Navigation Links
Battelle to Perform Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process
Date:10/28/2008

CAMBRIDGE, Mass. and COLUMBUS, Ohio, Oct. 28 /PRNewswire/ -- IntelligentMDx a developer and manufacturer of proprietary nucleic acid assays, today announced that it is working with the Battelle Eastern Science and Technology (BEST) Center to conduct assay performance verification studies of its nucleic acid-based diagnostic or 'smart' molecular diagnostic assays.

Under terms of the agreement Battelle will perform various testing of IntelligentMDx's Quantitative BK Virus (BKV) Real-Time PCR Assay to identify its performance characteristics. Financial terms of the agreement were not disclosed.

BKV has recently emerged as an important pathogen in nephropathy in kidney transplant patients and hemorrhagic cystitis in human stem cell transplant patients. The IntelligentMDx Quantitative BK Virus Real-Time PCR Assay can be utilized to track the course of infection and monitor response to treatment.

The biggest hurdle for a nucleic acid testing is that current reagent design methods do not specifically address the core set of challenge affecting reagent performance -- such as genetic diversity and other key performance metrics. IntelligentMDx has a proprietary process to manage the design, development and manufacturing of pathogen assays that are platform agnostic and adaptable to all nucleic acid detection methodologies. The IntelligentMDx process allows for rapid time to market.

About IntelligentMDx

IntelligentMDx(TM) develops and manufactures tests, under regulatory compliance, for a broad range of molecular based systems for use in clinical molecular diagnostics, drug development and applied science applications. Our mission is to rapidly translate the needs of the clinician, patient and partners into very specific, highly sensitive, robust clinically impactful tests, thus enabling caregivers worldwide to provide care with certainty(SM).

IntelligentMDx's competitive advantage incorporates intelligent software with assay development and manufacturing expertise within a Quality System compliant with both ISO and FDA current regulations. Our uniquely integrated modular test development process provides clinically impactful and novel nucleic-acid testing solutions including Real-Time PCR assays. The company is working to use its proprietary "symptom-based diagnostics" approach for disease detection. Our goal is to provide the end users with "smart" tests that detect several related diseases at once -- more quickly and more economically than current standard individual tests. The quality and breadth of our product candidate pipeline, platform-agnostic approach, scientific team and strategic collaborations and partnerships is enabling us to become a fully integrated molecular diagnostics company.

About Battelle

Battelle's Global Health and Life Sciences business delivers a comprehensive set of R&D services to solve complex challenges for government health agencies and medical device, biotechnology, and pharmaceutical firms. Including the national laboratories it manages or co-manages, Battelle oversees over $200 million annually in health and life sciences-research contributing to advances in medical devices, pharmaceuticals, public health, and next-generation diagnostics and therapeutics.

Battelle is the world's largest non-profit independent research and development organization, providing innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management, National Security, Energy Technology, and Health and Life Sciences. It advances scientific discovery and application by conducting $4 billion in global R&D annually through contract research, laboratory management and technology commercialization. Headquartered in Columbus, Ohio, Battelle oversees 20,400 employees in more than 120 locations worldwide, including six national laboratories which Battelle manages or co-manages for the U.S. Department of Energy.

Statements in this release, including those that may relate to revenue growth, trends in financial or operational performance, litigation, new product plans and business prospects are forward-looking statements. Actual results might differ materially from these statements due to risks and uncertainties, including the impact of competitive products and pricing, market acceptance of new products, market conditions and enforcement of intellectual property rights. A more detailed description of these risks and other risks applicable to IntelligentMDx are available upon request from IntelligentMDx. IntelligentMDx disclaims any intent or obligation to update these forward-looking statements.

CONTACT: For more information on IntelligentMDx, visit http://www.IntelligentMD.com or contact Corporate Communications, cc@IntelligentMD.com, 617-871-6400.

For more information on Battelle, visit http://www.battelle.org or contact Public Relations Manager Katy Delaney at (410) 306-8638 or at delaneyk@battelle.org.


'/>"/>
SOURCE IntelligentMDx
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Battelle and YuYu Pharma Create the First Joint Bioequivalence Test Experimentation Institution
2. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
5. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
6. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
7. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
8. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
9. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
10. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
11. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well ... VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and ... your workout. , After a successful launch in Sweden last year, the next ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who ... the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the ... and at 19 years of age, he joined the Navy and got married right out ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: ... published author, Sara Seymour, who lives in Lafayette, Indiana where she works in a ... iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book ...
(Date:1/20/2017)... ... ... Land of More and More”: a brilliant story for children and adults alike ... achievable answer. “The Land of More and More” is the creation of published author, ... where he works with the children’s ministry department. , Michael says that he ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Learning Management System: an On-demand E-learning system for Clinical and Regulatory education ... that is based on Aerolib`s successful education methodology of Disease Specific Documentation ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical ... new additions to its senior leadership team: W. ... Daniel Geffken as interim Chief Financial Officer. ... Pharm.D. has been promoted to Chief Clinical Development Officer. ... and Daniel to our management team, as both will ...
(Date:1/19/2017)... Accuray Incorporated (Nasdaq: ARAY ) ... to set the bar for excellence in customer satisfaction. ... satisfaction rating among radiation treatment delivery systems in the ... Intelligence Briefing™. The most recent ratings trend also shows ... peers for 11 of the past 12 quarters. ...
(Date:1/19/2017)... Fla. , Jan. 19, 2017  Sensus ... medical device company specializing in the treatment of ... as keloids, with superficial radiation therapy, today announced ... full year 2016 financial results on Thursday, February 2, ... Company will hold a conference call with the ...
Breaking Medicine Technology: